Dr. Zhu has extensive research and development experience within the biotechnology industry. Since 2017 Dr. Zhu is acting as Chief Scientific Officer at 3SBio. Before he served as Executive Vice President, Global Biopharmaceuticals, Kadmon Corporation, and President of Kadmon China. Prior to joining Kadmon, Dr. Zhu was Vice President and Global Head, Protein Sciences and Design, at Novartis and was responsible for the discovery, design and selection of novel biologics medicines that address various human diseases. Prior to Novartis, Dr. Zhu worked for over 12 years at ImClone Systems as Vice President of Antibody Technology and Immunology, and has led multiple teams responsible for the successful discovery and early development of several FDA-approved novel antibodies for various oncology indications, including cetuximab (Erbitux®), ramucirumab (Cyramza®), necitumumab (Portrazza®), and olaratumab (Latruvo®). Dr. Zhu is the inventor of both ramucirumab and necitumumab, and one of the major contributors to cetuximab and olaratumab.